Aben Gold Provides Drill Program Update at Justin Gold-Tungsten Project

Aben Gold is progressing its fully funded 2026 diamond drill program at the Justin Gold-Tungsten Project, completing 766m over 21 days (35m/day) as of Aug. 30, 2026, with 785 core samples collected. The 1,300m program has begun assay work: the first hole JN26-001 (341 samples) was cut and sent to Bureau Veritas on Aug. 26, while JN26-002 (227 samples) and JN26-003 (217 samples) are being prepared for dispatch. Visual massive sulphides and WO3 ultraviolet indications support ongoing drilling but no assay results are reported yet.

Analysis

This is a classic optionality setup: the market is paying for the possibility of an economically meaningful intercept, not for demonstrated cash flow. The near-term winner, if anything, is sentiment around junior precious/critical-mineral explorers, but the real economic beneficiaries are only those with repeatable grades and metallurgy; otherwise the move is just a tradable headline spike. In tungsten specifically, any credible domestic supply thesis matters because end-users are structurally exposed to China concentration, but that premium only accrues once continuity and recoveries are proven.

The key risk is that visible mineralization gets overcapitalized before assay data arrives. For microcap explorers, the first assay batch is usually the inflection point: positive numbers can create a 1-3 week squeeze, but weak or inconsistent results often trigger a financing overhang and a 30-50% retrace as attention fades. Over 6-18 months, even good geology still needs metallurgy, permits, and capex, so the value bridge from discovery to monetization remains long.

The contrarian view is that the current tape may be overpricing "proof" when only "evidence" exists. The cleanest expression is not to chase the name pre-assay, but to wait for verifiable lab results; if the first batch disappoints, the story likely shifts from discovery to dilution. If results surprise positively, the rerating could be sharp but should be treated as a trade, not an investment, until follow-up drilling shows continuity beyond a single hole.

Key Decisions for Investors

• Do not establish a core long in ABNAF before the first Bureau Veritas assays print; the pre-data setup is too binary and downside on disappointment is likely 30-50% from a momentum peak.
• If you want event-driven exposure, buy ABNAF only on confirmed assay strength and hold for 1-3 weeks; target a 2-3x move on a genuine economic intercept, with a hard exit if the stock fails to hold its first post-result gap.
• Use GDXJ as the cleaner sector expression if assay-driven optimism spills into junior explorers; it captures sympathy flow without single-asset dilution risk. Time horizon: 1-3 months.
• Set a watch item for the first assay batch and subsequent financing language; if management pivots to a placement quickly after release, treat that as a tell that the market is being used to fund the next round rather than to value the discovery.